Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
- Previous Close
21.31 - Open
21.62 - Bid 22.72 x --
- Ask 22.73 x --
- Day's Range
21.50 - 23.52 - 52 Week Range
15.36 - 36.99 - Volume
12,944,842 - Avg. Volume
8,104,174 - Market Cap (intraday)
9.079B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-2.61 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products in China and internationally. The company offers its products for oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection; MAILISHU for the treatment of postmenopausal women with osteoporosis; JUNMAIKANG, an immunological product; and MAIWEIJIAN for giant cell tumor of bone. The company's oncology products pipeline includes 9MW2821 which is in phase III clinical trial; 6MW3211, which is in phase II of clinical trial; 6MW3211 which is in phase II clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; and 8MW0511, which has completed phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; hematology product comprising 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is headquartered in Shanghai, China.
www.mabwell.comRecent News: 688062.SS
View More
Performance Overview: 688062.SS
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688062.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688062.SS
View MoreValuation Measures
Market Cap
8.52B
Enterprise Value
9.54B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
42.66
Price/Book (mrq)
5.43
Enterprise Value/Revenue
47.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.71%
Return on Equity (ttm)
-50.69%
Revenue (ttm)
199.78M
Net Income Avi to Common (ttm)
-1.04B
Diluted EPS (ttm)
-2.61
Balance Sheet and Cash Flow
Total Cash (mrq)
1.23B
Total Debt/Equity (mrq)
142.45%
Levered Free Cash Flow (ttm)
-1.06B